From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution.
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Identification of subjects at the early stages of Alzheimer's disease (AD) is fundamental for drug development and possible intervention or prevention of cognitive decline. The concept of mild cognitive impairment (MCI) evolved during the past two decades to define subjects at the transitional stage between normal aging and dementia. Evidence from cross-sectional and longitudinal studies has shown that MCI is associated with an increased risk of positive AD biomarkers and an increased annual conversion rate of 5%-17% to AD. The presence of AD biomarkers in subjects with MCI was associated with an even higher risk of progression to dementia. However, earlier clinical trials for pharmacotherapy in subjects with MCI were disappointing. To extend the spectrum of AD to an earlier stage before MCI, subjective cognitive decline (SCD) was introduced and was defined as self-reported cognitive decline before the deficits could be detected by cognitive tests. Subjects with SCD have an increased risk of underlying AD pathology. However, SCD can also develop secondary to other heterogeneous etiologies, including other neurodegenerative and psychiatric diseases, personality traits, physical conditions, and medication use. Several clinical and biomarker features were proposed to predict risk of conversion to AD in subjects with SCD. Further longitudinal studies are needed to support the validity of these high-risk features.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is informative for dementia research, since individuals with MCI have an increased annual conversion rate of 5–17% to Alzheimer’s disease (Cheng et al., 2017), and approximately 60% over a 15-year period of persons with SCD will continue to develop Alzheimer’s disease (Reisberg et al., 2008).”
From Mindfulness Training for People With Dementia and Their Caregivers: Rationale, Current Research, and Future Directions (2018) · cites this paper as Cheng et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 1×
“In 2011, the NIA-AA convened workgroups to revise diagnostic criteria for AD and its preclinical stages.(6,20,21) The NIA-AA core clinical criteria for MCI due to AD were essentially adopted from the Key Symposium criteria, while incorporation of biochemical and neuroimaging biomarkers was recommended in research sett…”
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“The NIA-AA core clinical criteria for MCI due to AD were essentially adopted from the Key Symposium criteria, while incorporation of biochemical and neuroimaging biomarkers was recommended in research settings to stratify the level of certainty of underlying Alzheimer’s pathology.(21) During”
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864 · cited 1×
“To broaden the concept of MCI, the Key Symposium was held in Sweden and published consensus criteria for MCI in 2004.(10,11) To emphasize the heterogeneity of the clinical presentation and multiple underlying etiologies of MCI, the Key Symposium criteria expanded the definition of MCI beyond the memory domain and furt…”
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 3×
“Following the development of biochemical and neuroimaging biomarkers, the National Institute on Aging and the Alzheimer’s Association (NIA-AA) recommended a staging schema for preclinical AD based on biomarker status.(6) Subjects without cognitive decline are classified”
The Global Deterioration Scale for assessment of primary degenerative dementia
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,986 · cited 1×
“that affect complex occupational and social activities but do not yet meet the criteria for dementia.(7,8) In 1999, Petersen et al redefined MCI as a syndrome of cognitive decline beyond that expected for an individual’s age and education level, but that does not notably interfere with activities of daily living.”
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946 · cited 1×
“To broaden the concept of MCI, the Key Symposium was held in Sweden and published consensus criteria for MCI in 2004.(10,11) To emphasize the heterogeneity of the clinical presentation and multiple underlying etiologies of MCI, the Key Symposium criteria expanded the definition of MCI beyond the memory domain and furt…”
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Cited by
Items 101–150 of 150
Xu, X., Liu, X., Liu, X.-L., Wang, X., Zhang, W., Huang, X.-F., Jia, F.-Y., Kong, P., & Han, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087117 · Cited by 3
“Cognitive impairment generally refers to various degrees of compromised cognitive function due to diverse factors, ranging from mild cognitive impairment to dementia [1].”
BackgroundSela, Y. (2023) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2022-0047 · Cited by 5
Kim, A. Y., Chu, S. H., Oh, S. S., Lee, E. M., Choi, J., & Kim, W. J. (2024) · Psychiatry Investigation · doi:10.30773/pi.2023.0403 · Cited by 3
“8-11 Relying solely on SCD is inadequate for the reliable detection of pre-clinical AD, highlighting the need for exploring various cognitive domains beyond memory.”
BackgroundPedroli, E., Bruni, F., Mancuso, V., Cavedoni, S., Bigotto, F., Panigada, J., Rossi, M., Boilini, L., Goulene, K., Stramba‐Badiale, M., et al. (2025) · Technologies · doi:10.3390/technologies13030096 · Cited by 4
Al-Tal, S., Alkhatib, B. M., & Agraib, L. M. (2025) · Journal of Aging Research · doi:10.1155/jare/7358242 · Cited by 4
“In case of mild cognitive decline (which is defned as the in-between stage between typical thinking skills and dementia [18]) or if there was any problem understanding or answering specifc questions, usually, a family member living with the participant in the same household was asked to answer…”
Zhuang, Y., Huang, H., Fu, Z., Zhang, J., & Cai, Q. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01185-2 · Cited by 6
Lazarou, I., Nikolopoulos, S., Dimitriadis, S. I., Kompatsiaris, I. Y., Spylioti, M., & Tsolaki, M. (2019) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/dtqeh · Cited by 3
Allam, A. K., Allam, V., Reddy, S., Patel, A., Froudarakis, E., ROHREN, E. M., Sheth, S. A., & Papageorgiou, T. D. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.03.582390 · Cited by 3
“…to Alzheimer’s disease, is a state of cognitive decline without objective cognitive deficits on neuropsychological testing or of any other neurological or psychiatric diagnosis (Cheng et al., 2017; Hill et al., 2016; Killeen et al., 2023; Pedro et al., 2016; Wang et al., 2020; Zheng et al., 2018).”
BackgroundYuan, Z., Huang, Z., Li, C., Li, S., Ren, Q., Xia, X., Jiang, Q., Zhang, D., Zhu, Q., & Meng, X. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1527323 · Cited by 4
Yan, Y., Yan, H., & Li, J. (2025) · The British Journal of Social Work · doi:10.1093/bjsw/bcaf287 · Cited by 2
Gómez‐Soria, I., Oliván‐Blázquez, B., Aguilar‐Latorre, A., Cuenca‐Zaldívar, J. N., Magallón-Botaya, R. M., & Calatayud, E. (2025) · Anales del Sistema Sanitario de Navarra · doi:10.23938/assn.1118 · Cited by 3
Neudorf, B., Koblinsky, N. D., Power, K. A., Binns, M. A., Fiocco, A. J., Rotenberg, S., Marzolini, S., OH, P. I., Thornton, J. S., Ajwani, F., et al. (2025) · Pilot and Feasibility Studies · doi:10.1186/s40814-025-01626-4 · Cited by 2
Wang, L., Dong, S., Zhao, C., Gao, Z., Jiang, L., Zhang, R., Shen, T., Guo, Y., Zhou, H., & Xu, S. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14010 · Cited by 7
Functional MRI Studies of Memory in Aging, Mild Cognitive Impairment, and Alzheimer’s Disease
Zhu, J. K., Risacher, S. L., Wishart, H. A., & Saykin, A. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-10909-6_30 · Cited by 2
Alonso‐Recio, L., Mendoza, L., & Serrano, J. M. (2024) · Applied Neuropsychology Adult · doi:10.1080/23279095.2024.2443174 · Cited by 1
Raymond, B., Bélanger, C., Hudon, C., Grenier, S., & CIMA-Q Group (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251319538 · Cited by 2
“51 For the GAI, three dimensions are described in Bandari et al., 28 namely cognitive anxiety (items 1, 2, 3, 5, 8, 9, 11, 14, 16), somatic anxiety (items 7, 12, 15, 18), and arousal (items 4, 6, 10, 13, 20).”
Emerging Nanoparticle Drug Delivery Approaches for the Treatment of Alzheimer’s Disease: A Review
Mishra, D., & Yadav, S. (2025) · International Journal of Newgen Research in Pharmacy & Healthcare · doi:10.61554/ijnrph.v3i1.2025.171 · Cited by 2
Allevi, D., Luchicchi, A., & Orefice, N. S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118381 · Cited by 1
Detection of Alzheimer's disease using 3D-CNN model based on multimodal connectome
Dana, A. M. A., Karami, M., & Ghasemi, J. (2025) · Applied Soft Computing · doi:10.1016/j.asoc.2025.114006 · Cited by 1
Nwakasi, C. C., & Nweke, C. (2025) · Research on Aging · doi:10.1177/01640275251409700 · Cited by 1
“While dementia risk increases notably after age 65 (Kramarow, 2024), research indicates that its underlying pathophysiological processes may begin years or even decades before clinical symptoms appear (Cheng et al., 2017; Liss et al., 2021).”
Imaging Diagnosis of Mild Cognitive Impairment: A Bibliometric Analysis (1999–2024)
Xie, J., Li, S., li, K., & Sun, K. (2025) · Brain and Behavior · doi:10.1002/brb3.71144 · Cited by 1
Bartels, C., Meiberth, D. U., Frommann, I., Wagner, M., Belz, M., & Schild, A. (2025) · Zeitschrift für Neuropsychologie · doi:10.1024/1016-264x/a000424 · Cited by 1
Copolymer-1 as a potential therapy for mild cognitive impairment
Abraham, D. I., Salazar, F. E., & Ibarra, A. (2022) · Brain and Cognition · doi:10.1016/j.bandc.2022.105892 · Cited by 1
Santos-Rocha, P., Bonifácio, A., de Almeida, A. Q., Alcobia, P., Erskine, A., Conceição, M., Marques-Reis, J. P., Burghardt, T., Morgado, P., & Miranda, B. (2024) · Research Square · doi:10.21203/rs.3.pex-2623/v1 · Cited by 1
Dementia: Are we all on the spectrum?
Jewell, A. J. (2018) · Journal of Religion Spirituality & Aging · doi:10.1080/15528030.2018.1474160
Information Processing Speed in Ageing: Is it task dependent?
Torrens‐Burton, A. (2018) · Cronfa (Swansea University) · doi:10.23889/suthesis.40835
Mild Cognitive Impairment – History, Diagnosis and Treatment
Sinoff, G. (2018) · Neurology - Research & Surgery · doi:10.33425/2641-4333.1002
Carr, S. (2018) · TSpace (University of Toronto)
Predementia Neurocognitive Disorders in the Elderly
Levin, O. S. (2020) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-020-00956-5
Стратегия мембранопротекции в фармакотерапии сосудистых когнитивных расстройств
Burchinsky, S. G. (2021) · INTERNATIONAL NEUROLOGICAL JOURNAL · doi:10.22141/2224-0713.16.8.2020.221959 · Cited by 1
Mai, W., Tang, L., Wei, Y., Zhou, L., Zou, Z., Teng, J., Su, J., Nong, X., Yu, B., Li, C. V., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-424514/v1
Preserved cognition in elderly with intact rhinal cortexPreprint
Sepehrband, F., Lynch, K. M., Gasperi, A. S., Bienkowski, M. S., Wang, X., Chui, H. C., Toga, A. W., & Initiative, T. A. D. N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.30.494074
“Prior to the formal onset of AD, the transitional state between normal aging and dementia is known as mild cognitive impairment (MCI) (Cheng et al., 2017).”
BackgroundDuman, F. (2022) · The Turkish Journal of Geriatrics · doi:10.31086/tjgeri.2022.287
Recognition and treatment of mild cognitive impairment in Serbian general practice
Kostić, M., Fišeković-Kremić, M., & Kis-Veljkovic, M. (2023) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh210620007k
Gill, S. S. (2024) · Evidence-Based Nursing · doi:10.1136/ebnurs-2023-103845
Metacognitive Rehabilitation in the Elderly: the Mind the Gap Metacognitive Program
Orfei, M. D. (2024) · Mental Health & Human Resilience International Journal · doi:10.23880/mhrij-16000236
Copolímero-1 como terapia potencial para el deterioro cognitivo leve
Fuentes-Fernández-Cueto, M., & Ibarra, A. (2023) · Neurología, Neurocirugía y Psiquiatría · doi:10.35366/115406
Pereira, M. L., Caramelli, P., de Sá, V. M., Rocha, P. H. M., de Oliveira, J. P. G., de Amorim, R. P., da Silva, E. V., Delboni, V. S., Barbosa, M. T., de Miranda, L. F. J. R., et al. (2024) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0044-1787138 · Cited by 2
“14 Few studies analyzed the outcome of individuals with memory complaints followed up at primary health care centers in low-and middle-income countries.”
BackgroundSubjektívny pokles kognície: koncept a súvislosti
Filozofická fakulta Univerzity Komenského, B., Krakovska, S., Hajdúk, M., Heretik, A., Košutzká, Z., & Brandoburová, P. (2024) · Ceskoslovenska psychologie · doi:10.51561/cspsych.68.4.388 · Cited by 2
Udoh, I. I. (2024) · University of North Texas Digital Library (University of North Texas) · doi:10.12794/metadc2356148
Chiaravalloti, N. D., Weber, E., Costa, S. L., Lengenfelder, J., Maloku, D., Moore, N. B., & DeLuca, J. (2025) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000543682 · Cited by 1
“Prevalence rates for MCI range from 7 to 25% over age 60 [1, 3 – 5], with risk increasing with age [6].”
Zhang, M., Rodriguez, A., Weir, R. L., Hanmer, J., Harrison, J. M., & Edelen, M. O. (2025) · Advances in Patient-Reported Outcomes · doi:10.1016/j.apro.2025.100190 · Cited by 1
Mace, R. A., Stewart-McLellan, M. J., Law, M. E., Harley, D., Ritchie, C. S., Bartels, S. J., Okereke, O. I., Hoeppner, B. B., Brewer, J. A., Amariglio, R. E., et al. (2025) · The Gerontologist · doi:10.1093/geront/gnaf159
Correlates of mild behavioural impairment in older adults: a scoping review
Kang, B., Yoon, S., Jeong, I., Hong, D., & Kim, J. I. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06469-5 · Cited by 2
“Although there is no definitive treat-ment for dementia, early identification and interventions targeting modifiable risk factors may help delay progression and reduce the burden of decline in cognitive and behavioural functioning [3, 4].”
Thongwachira, C., Harnirattisai, T., & Morris, D. L. (2025) · The Journal of Behavioral Science · doi:10.69523/tjbs.2025.275134
Qian, Y., Doig, A. J., Michopoulou, S. K., & Costen, F. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45313
Topçuoğlu, M., Guler, A., Halil, M. G., Hanağası, H., Midi, I., Saka, B., & Topçuoğlu, E. S. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1966218
Alonso‐Recio, L., Carvajal, F., & Serrano, J. M. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261489584
Chen, T., Wang, J., Varghese, S., Tian, J., Amariglio, R. E., Zhou, L., Marshall, G. A., & Wang, L. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70525
Self-citation
Metadata
- Authors
- Cheng, Y.-W., Chen, T.-F., & Chiu, M.-J.
- Affiliations
- National Taiwan University Hospital (TW)
- National Taiwan University (TW)
- Corresponding author
- Chiu, Ming-Jang
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2017-02
- Volume
- Volume 13
- Pages
- 491-498
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC5317337
- OpenAlex
- W2588980103
- Cited by
- 150
- References
- 98
- Citations by year
- 2026: 4 · 2025: 28 · 2024: 18 · 2023: 16 · 2022: 15 · 2021: 17 · 2020: 15 · 2019: 19 · 2018: 14 · 2017: 4
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- mild cognitive impairment, subjective cognitive decline, Alzheimer's disease, early detection of dementia, conversion to dementia, Alzheimer's disease biomarkers, risk prediction, normal aging, neurodegenerative diseases, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.